Abstract
The insulin-like growth factor (IGF)-1 and transforming growth factor (TGF)-β signal pathways are both recognized as important in regulating cancer prognosis, such as the epithelial-to-mesenchymal transition (EMT) and cell invasion. However, cross-talk between these two signal pathways in glioblastoma multiforme (GBM) is still unclear. In the present study, by analyzing data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GSE) 4412, GBM patients with higher IGF-1 levels exhibited poorer survival. Genes positively correlated with IGF-1 were enriched in EMT and TGF-β signal pathways. IGF-1 treatment enhanced mesenchymal marker expressions and GBM cell invasion. A significant positive correlation was observed for IGF-1 with TGF-β1 (TGFB1) or TGF-β receptor 2 (TGFBR2), both of which participate in TGF-β signaling and are risk genes in the GBM process. IGF-1 stimulation promoted both TGFB1 and TGFBR2 expressions. LY2157299, a TGF-β signaling inhibitor, attenuated IGF-1-enhanced GBM cell invasion and mesenchymal transition. By analyzing IGF-1-regulated microRNA (miR) profiles, miR-4286 was found to be significantly downregulated in IGF-1-treated cells and could be targeted to both TGFB1 and TGFBR2. Overexpression of miR-4286 significantly attenuated expressions of the IGF-1-mediated mesenchymal markers, TGFB1 and TGFBR2. Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-β signaling axis. Finally, our results suggested that miR-4286 might act as a tumor suppressive microRNA in inhibiting IGF-1-enhanced GBM cell invasion. In conclusion, IGF-1 is connected to TGF-β signaling in regulating the mesenchymal transition and cell invasion of GBM through inhibition of miR-4286. Our findings provide new directions and mechanisms for exploring GBM progression.
Similar content being viewed by others
Data Availability
The data that support the findings of this study are available from the corresponding author, Ku-Chung Chen, upon reasonable request.
References
Agarwal V, Bell GW, Nam JW, Bartel DP (2015) Predicting effective microRNA target sites in mammalian mRNAs. eLife. https://doi.org/10.7554/eLife.05005
Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, Martinez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Pena JG, Trevino V (2013) SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS ONE 8(9):e74250. https://doi.org/10.1371/journal.pone.0074250
Alsina-Sanchis E, Figueras A, Lahiguera A, Vidal A, Casanovas O, Graupera M, Villanueva A, Vinals F (2016) The TGFbeta pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels. Int J Cancer 139(8):1894–1903. https://doi.org/10.1002/ijc.30233
Bryukhovetskiy I, Shevchenko V (2016) Molecular mechanisms of the effect of TGF-beta1 on U87 human glioblastoma cells. Oncol Lett 12(2):1581–1590. https://doi.org/10.3892/ol.2016.4756
Cevenini A, Orru S, Mancini A, Alfieri A, Buono P, Imperlini E (2018) Molecular signatures of the insulin-like growth factor 1-mediated epithelial-mesenchymal transition in breast, lung and gastric cancers. Int J Mol Sci. https://doi.org/10.3390/ijms19082411
Chen KC, Chen PH, Ho KH, Shih CM, Chou CM, Cheng CH, Lee CC (2019) IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway. PLoS ONE 14(12):e0225913. https://doi.org/10.1371/journal.pone.0225913
Chung IF, Chang SJ, Chen CY, Liu SH, Li CY, Chan CH, Shih CC, Cheng WC (2017) YM500v3: a database for small RNA sequencing in human cancer research. Nucleic Acids Res 45(D1):D925–d931. https://doi.org/10.1093/nar/gkw1084
Danielpour D, Song K (2006) Cross-talk between IGF-I and TGF-beta signaling pathways. Cytokine Growth Factor Rev 17(1–2):59–74. https://doi.org/10.1016/j.cytogfr.2005.09.007
Dweep H, Gretz N (2015) miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods 12(8):697. https://doi.org/10.1038/nmeth.3485
Fedele M, Cerchia L, Pegoraro S, Sgarra R, Manfioletti G (2019) Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma. Int J Mol Sci. https://doi.org/10.3390/ijms20112746
Gibaja A, Aburto MR, Pulido S, Collado M, Hurle JM, Varela-Nieto I, Magarinos M (2019) TGFbeta2-induced senescence during early inner ear development. Sci Rep 9(1):5912. https://doi.org/10.1038/s41598-019-42040-0
Grandori C, Cowley SM, James LP, Eisenman RN (2000) The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16:653–699. https://doi.org/10.1146/annurev.cellbio.16.1.653
Guo D, Ye Y, Qi J, Zhang L, Xu L, Tan X, Yu X, Liu Q, Liu J, Zhang Y, Ma Y, Li Y (2016) MicroRNA-181a-5p enhances cell proliferation in medullary thymic epithelial cells via regulating TGF-beta signaling. Acta Biochim Biophys Sin 48(9):840–849. https://doi.org/10.1093/abbs/gmw068
Guvakova MA (2007) Insulin-like growth factors control cell migration in health and disease. Int J Biochem Cell Biol 39(5):890–909. https://doi.org/10.1016/j.biocel.2006.10.013
Hernandez DM, Kang JH, Choudhury M, Andrianifahanana M, Yin X, Limper AH, Leof EB (2020) IPF pathogenesis is dependent upon TGFbeta induction of IGF-1. FASEB J 34(4):5363–5388. https://doi.org/10.1096/fj.201901719RR
Ho KH, Chang CK, Chen PH, Wang YJ, Chang WC, Chen KC (2018) miR-4725-3p targeting stromal interacting molecule 1 signaling is involved in xanthohumol inhibition of glioma cell invasion. J Neurochem 146(3):269–288. https://doi.org/10.1111/jnc.14459
Iwadate Y, Matsutani T, Hirono S, Shinozaki N, Saeki N (2016) Transforming growth factor-beta and stem cell markers are highly expressed around necrotic areas in glioblastoma. J Neuro-Oncol 129(1):101–107. https://doi.org/10.1007/s11060-016-2145-6
Kang Y, Massague J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118(3):277–279. https://doi.org/10.1016/j.cell.2004.07.011
Karpinski BA, Morle GD, Huggenvik J, Uhler MD, Leiden JM (1992) Molecular cloning of human CREB-2: an ATF/CREB transcription factor that can negatively regulate transcription from the cAMP response element. Proc Natl Acad Sci USA 89(11):4820–4824. https://doi.org/10.1073/pnas.89.11.4820
Li C, Li J, Wu D, Han G (2016) The involvement of survivin in insulin-like growth factor 1-induced epithelial-mesenchymal transition in gastric cancer. Tumour Biol 37(1):1091–1096. https://doi.org/10.1007/s13277-015-3909-x
Li H, Xu L, Zhao L, Ma Y, Zhu Z, Liu Y, Qu X (2015) Insulin-like growth factor-I induces epithelial to mesenchymal transition via GSK-3beta and ZEB2 in the BGC-823 gastric cancer cell line. Oncol Lett 9(1):143–148. https://doi.org/10.3892/ol.2014.2687
Lin YC, Lin JC, Hung CM, Chen Y, Liu LC, Chang TC, Kao JY, Ho CT, Way TD (2014) Osthole inhibits insulin-like growth factor-1-induced epithelial to mesenchymal transition via the inhibition of PI3K/Akt signaling pathway in human brain cancer cells. J Agric Food Chem 62(22):5061–5071. https://doi.org/10.1021/jf501047g
Ling C, Wang X, Zhu J, Tang H, Du W, Zeng Y, Sun L, Huang JA, Liu Z (2019) MicroRNA-4286 promotes cell proliferation, migration, and invasion via PTEN regulation of the PI3K/Akt pathway in non-small cell lung cancer. Cancer Med 8(7):3520–3531. https://doi.org/10.1002/cam4.2220
Liu CA, Chang CY, Hsueh KW, Su HL, Chiou TW, Lin SZ, Harn HJ (2018a) Migration/invasion of malignant gliomas and implications for therapeutic treatment. Int J Mol Sci. https://doi.org/10.3390/ijms19041115
Liu F, Sun Y, Liu B, Lu J, Li H, Zhu H, Gao H, Zhou X, Chang H (2018b) Insulin-like growth factor-1 induces epithelial-mesenchymal transition in hepatocellular carcinoma by activating survivin. Oncol Rep 40(2):952–958. https://doi.org/10.3892/or.2018.6516
Llobet-Navas D, Rodriguez-Barrueco R, Castro V, Ugalde AP, Sumazin P, Jacob-Sendler D, Demircan B, Castillo-Martin M, Putcha P, Marshall N, Villagrasa P, Chan J, Sanchez-Garcia F, Pe'er D, Rabadan R, Iavarone A, Cordon-Cardo C, Califano A, Lopez-Otin C, Ezhkova E, Silva JM (2014) The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland. Genes Dev 28(7):765–782. https://doi.org/10.1101/gad.237404.114
Lo HW (2010) Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets 10(8):840–848. https://doi.org/10.2174/156800910793357970
Luo D, Xu X, Li J, Chen C, Chen W, Wang F, Xie Y, Li F (2018) The PDK1/cJun pathway activated by TGFbeta induces EMT and promotes proliferation and invasion in human glioblastoma. Int J Oncol 53(5):2067–2080. https://doi.org/10.3892/ijo.2018.4525
Ma C, Wei F, Xia H, Liu H, Dong X, Zhang Y, Luo Q, Liu Y, Li Y (2017) MicroRNA-10b mediates TGF-beta1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition. Int J Oncol 50(5):1739–1748. https://doi.org/10.3892/ijo.2017.3947
McCarthy TL, Centrella M (2015) Androgen receptor activation integrates complex transcriptional effects in osteoblasts, involving the growth factors TGF-beta and IGF-I, and transcription factor C/EBPdelta. Gene 573(1):129–140. https://doi.org/10.1016/j.gene.2015.07.037
Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B, Vanderkerken K (2004) Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer 90(5):1076–1083. https://doi.org/10.1038/sj.bjc.6601613
Park GB, Kim D (2018) Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K in a cell-type-dependent manner to induce lipogenesis-dependent epithelial-mesenchymal transition through the regulation of ADAM10 and ADAM17. Mol Cell Biochem 439(1–2):199–211. https://doi.org/10.1007/s11010-017-3148-0
Petz LN, Ziegler YS, Schultz JR, Nardulli AM (2004) Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol Endocrinol 18(3):521–532. https://doi.org/10.1210/me.2003-0105
Rohrmann S, Linseisen J, Becker S, Allen NE, Schlehofer B, Overvad KK, Olsen A, Tjonneland AAM, Melin B, Lund E, Vineis P, Grioni S, Tumino R, Palli D, Matiello A, Bonet C, Chirlaque M-D, Sanchez M-J, Rodriguez L, Dorronsoro M, Ardanaz E, Lagiou P, Trichopoulou A, Trichopoulos D, Dossus L, Grote VA, Boeing H, Aleksandrova K, Bueno-de-Mesquita HB, van Duijnhoven F, Peeters PHM, Khaw K-T, Wareham NJ, Key TJ, Rinaldi S, Romieux I, Gallo V, Michaud DS, Riboli E, Kaaks R (2011) Concentrations of IGF-I and IGFBP3 and brain cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomark Prev. https://doi.org/10.1158/1055-9965.EPI-11-0179
Roy LO, Poirier MB, Fortin D (2018) Differential expression and clinical significance of transforming growth factor-beta isoforms in GBM tumors. Int J Mol Sci. https://doi.org/10.3390/ijms19041113
Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28(1):20–47. https://doi.org/10.1210/er.2006-0001
Seystahl K, Papachristodoulou A, Burghardt I, Schneider H, Hasenbach K, Janicot M, Roth P, Weller M (2017) Biological role and therapeutic targeting of TGF-beta3 in glioblastoma. Mol Cancer Ther 16(6):1177–1186. https://doi.org/10.1158/1535-7163.MCT-16-0465
Sirianni R, Nogueira E, Bassett MH, Carr BR, Suzuki T, Pezzi V, Andò S, Rainey WE (2010) The AP-1 family member FOS blocks transcriptional activity of the nuclear receptor steroidogenic factor 1. J Cell Sci 123(Pt 22):3956–3965. https://doi.org/10.1242/jcs.055806
Song Y, Chen Y, Li Y, Lyu X, Cui J, Cheng Y, Zheng T, Zhao L, Zhao G (2019) Resveratrol suppresses epithelial-mesenchymal transition in GBM by regulating Smad-dependent signaling. BioMed Res Int 2019:1321973. https://doi.org/10.1155/2019/1321973
Tsunoda S, Avezov E, Zyryanova A, Konno T, Mendes-Silva L, Pinho Melo E, Harding HP, Ron D (2014) Intact protein folding in the glutathione-depleted endoplasmic reticulum implicates alternative protein thiol reductants. eLife 3:e03421. https://doi.org/10.7554/eLife.03421
Urbanska K, Sokolowska J, Szmidt M, Sysa P (2014) Glioblastoma multiforme - an overview. Contemp Oncol (Pozn) 18(5):307–312. https://doi.org/10.5114/wo.2014.40559
Walsh LA, Damjanovski S (2011) IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-β1 resulting in epithelial to mesenchymal transition. Cell Commun Signal 9(1):10. https://doi.org/10.1186/1478-811x-9-10
Weroha SJ, Haluska P (2012) The insulin-like growth factor system in cancer. Endocrinol Metab Clin N Am 41(2):335–350. https://doi.org/10.1016/j.ecl.2012.04.014
Whitmarsh AJ (2007) Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. Biochem Biophys Acta 1773(8):1285–1298. https://doi.org/10.1016/j.bbamcr.2006.11.011
Zhu VF, Yang J, Lebrun DG, Li M (2012) Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis. Cancer Lett 316(2):139–150. https://doi.org/10.1016/j.canlet.2011.11.001
Zumkeller W, Westphal M (2001) The IGF/IGFBP system in CNS malignancy. Mol Pathol 54(4):227–229. https://doi.org/10.1136/mp.54.4.227
Acknowledgements
This study was sponsored by the Shin Kong Wu Ho-Su Memorial Hospital, Taiwan (2018SKHADR030 to Chin-Cheng Lee); the Ministry of Science and Technology, Taiwan (Contract Grant No. MOST 106-2320-B-038-051-MY3 to Ku-Chung Chen and MOST 108-2314-B-038-110 to Chwen-Ming Shih); Taipei City Government (Contract Grant No. 10801-62-082 to Ann-Jeng Liu); Taipei City Hospital Ren-Ai Branch (Contract Grant No. TPCH-109-10 to Ann-Jeng Liu); and Taipei Medical University-Shin Kong Wu Ho-Su Memorial Hospital, Taiwan (intramural grant no. SKH-TMU-107-03 to Ku-Chung Chen). We thank the National RNAi Core Facility at Academia Sinica, Taiwan for providing shRNA reagents and related services. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Funding
This study was sponsored by the Shin Kong Wu Ho-Su Memorial Hospital, Taiwan (2018SKHADR030 to Chin-Cheng Lee); the Ministry of Science and Technology, Taiwan (Contract Grant No. MOST 106-2320-B-038-051-MY3 to Ku-Chung Chen and MOST 108-2314-B-038-110 to Chwen-Ming Shih); Taipei City Government (Contract Grant No. 10801-62-082 to Ann-Jeng Liu); Taipei City Hospital Ren-Ai Branch (Contract Grant No. TPCH-109-10 to Ann-Jeng Liu); and Taipei Medical University-Shin Kong Wu Ho-Su Memorial Hospital, Taiwan (Intramural Grant No. SKH-TMU-107-03 to Ku-Chung Chen).
Author information
Authors and Affiliations
Contributions
KH, CL, and KC conceived of the presented idea. KH, PC, and YL carried out the experiment. KH and PC wrote the manuscript. CS, CC, and AL verified the analytical methods. CL and KC supervised the findings of this work and contributed to the final version of the manuscript. All authors discussed the results, provided critical feedback, and helped shape the research, analysis and manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest associated with this work.
Informed Consent
All authors have approved about participating in this study. All authors have read and approved submission of the manuscript. The material in the manuscript has not been published and is not been considered for publication elsewhere in whole or in part in any language. No authors have potential conflicts of interest that relate to the manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ho, KH., Chen, PH., Shih, CM. et al. miR-4286 is Involved in Connections Between IGF-1 and TGF-β Signaling for the Mesenchymal Transition and Invasion by Glioblastomas. Cell Mol Neurobiol 42, 791–806 (2022). https://doi.org/10.1007/s10571-020-00977-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-020-00977-1